| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 7,371,574
- Publication Date: May 13, 2008
- Appl. No: 10/040128
- Application Filed: January 02, 2002
- Assignees: Imclone Systems, Inc. (New York, NY, US)
- Claim: 1. An isolated monoclonal antibody or an isolated fragment thereof capable of specifically binding to a site on a mouse or human VE-cadherin, said site being within the about first 15 N-terminal amino acids of domain 1 of the VE-cadherin, wherein said antibody or fragment thereof is capable of inhibiting VE-cadherin mediated adherens junction formation in vitro but does not exert any significant or substantial effect on paracellular permeability in vitro.
- Claim: 2. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof does not exert any significant or substantial effect on vascular permeability in vitro.
- Claim: 3. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof is substantially non-toxic when administered to an animal or mammal.
- Claim: 4. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof inhibits angiogenesis in vivo or in vitro or inhibits minor metastasis.
- Claim: 5. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof inhibits formation of new adherens junctions without disturbing existing adherens junctions.
- Claim: 6. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody is murine monoclonal antibody E4B9 of ATCC accession number PTA-1618.
- Claim: 7. A hybridoma which produces the monoclonal antibody of claim 1 .
- Claim: 8. A hybridoma ATCC of Accession No. PTA-1618 which produces the monoclonal antibody of claim 7 .
- Claim: 9. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof is a single chain antibody, is humanized, is chimerized or is bispecific.
- Claim: 10. The monoclonal antibody or fragment thereof of claim 1 , wherein said monoclonal antibody or fragment thereof is fused to a heterologous polypeptide.
- Claim: 11. A pharmaceutical composition comprising the monoclonal antibody or fragment thereof of any one of claims 1 - 6 , and 9 - 10 and a pharmaceutically acceptable carrier or diluent.
- Current U.S. Class: 435/334
- Patent References Cited: 5597725 January 1997 Suzuki ; 5646250 July 1997 Suzuki ; 2003/0206902 November 2003 Liao et al. ; 2005/0222037 October 2005 Blaschuk et al. ; WO 99/57149 November 1999
- Other References: Corada et al. Blood, vol. 97, No. 6, Mar. 2001. cited by examiner ; Greenspan et al. Nature Biotechnology 7:936-937 1999. cited by examiner ; Database IMSDRUGNEWS (R & D Focus Drug News, Nov. 17, 1997). cited by examiner ; Skolnick et al. (Trends Biotechnol. 2000; 18 (1): 34-39). cited by examiner ; Bowie et al. (Science 1990; 257: 1306-1310). cited by examiner ; Burgess et al. (Journal of Cell Biology 1990; 111: 2129-2138). cited by examiner ; Lazar et al. (Molecular and Cellular Biology, 1988, 8: 1247-1252). cited by examiner ; Luque et al. (Biochem. Nov. 19, 2002; 41 (46): 13663-13671). cited by examiner ; Vucic et al. (J. Biol. Chem. Dec. 18, 1998; 273 (51): 33915-33921). cited by examiner ; Takada et al. (Mol. Endocrinol. 2000; 14 (5): 733-740). cited by examiner ; Guo et al. (Proc. Natl. Acad. Sci. USA. Jun. 22, 2004; 101 (25): 9205-9210). cited by examiner ; Gura (Science. 1997; 278: 1041-1042). cited by examiner ; Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776). cited by examiner ; Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836). cited by examiner ; Schuh (Toxicologic Pathology. 2004; 32 (Suppl. 1): 53-66). cited by examiner ; Bibby (Eur. J. Cancer. Apr. 2004; 40 (6): 852-857). cited by examiner ; Peterson et al. (Eur. J. Cancer. 2004; 40: 837-844). cited by examiner ; Dennis (Nature. Aug. 7, 2006; 442: 739-741). cited by examiner ; Navarro et al. (J. Cell Biol. Mar. 23, 1998; 140 (6): 1475-1484). cited by examiner ; Lampugnani et al. (J. Cell. Biol. 1992; 118: 1511-1522). cited by examiner ; Yang et al. (Am. J. Pathol. Sep. 1999; 155 (3): 887-895). cited by examiner ; Bach et al. (J. Biol. Chem. Nov. 13, 1998; 273 (46): 30719-30728). cited by examiner ; May et al. (Blood. Jun. 1, 2005; 105 (11): 4337-4344). cited by examiner ; Liao et al. (Cancer Res. Dec. 15, 2000; 60: 6805-6810). cited by examiner ; Corada et al. (Blood. Aug. 1, 2002; 100 (3): 905-911). cited by examiner ; Carmeliet et al., “Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis,” Cell, vol. 98, Jul. 23, 1999, pp. 147-157. cited by other ; Vittet et al., “Targeted Null-mutation in the Vascular Endothelial-Cadherin Gene Impairs the Organization of Vascular-like Structures in Embryoid Bodies,” Proc. Natl. Acad. Sci. USA, vol. 94, Jun. 1997, pp. 6273-6278. cited by other ; Caveda et al., “Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin),” J. Clin. Invest., vol. 98, No. 4, Aug. 1996, pp. 886-893. cited by other ; Corada et al., “Vascular Endothelial-cadherin is an Important Determinant of Microvascular Integrity In Vivo,” Proc. Natl. Acad. Sci. USA, vol. 96, Aug. 1999, pp. 9815-9820. cited by other ; Uemura et al., “The Cadherin Superfamily at the Synapse: More Members, More Missions,” Cell, vol. 93, Jun. 26, 1998, pp. 1095-1098. cited by other ; Bach et al., “VE-Cadherin Mediates Endothelial Cell Capillary Tube Formation in Fibrin and Collagen Gels,” Experimental Cell Research, vol. 238, No. 2, 1998, pp. 324-334. cited by other ; Breier et al., “Molecular Cloning and Expression of Murine Vascular Endothelial-Cadherin in Early Stage Development of Cardiovascular System,” Blood, vol. 87, No. 2, Jan. 15, 1996, pp. 630-641. cited by other ; Maschio et al., “Polymorphonuclear Leukocyte Adhesion Triggers the Disorganization of Endothelial Cell-to-Cell Adherens Junctions,” The Journal of Cell Biology, vol. 135, No. 2, Oct. 1996, pp. 497-510. cited by other ; Martin-Padura et al., “Functional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily that Distributes at Intercellular Junctions and Modulates Monocyte Transmigration,” The Journal of Cell Biology, vol. 142, No. 1, Jul. 13, 1998, pp. 117-127. cited by other ; Liao et al., “Identification of antibody-based VE-cadherin antagonists for the application of anti-angiogenesis therapy,” Proc. Nat'l Acad. Sci. USA, vol. 41, Mar. 2000, abstract #4096. cited by other ; Breviario et al., “Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), and endothelium-specific cadherin,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, No. 8, Aug. 1995, pp. 1229-1239. cited by other ; Haselton et al., “Role of cadherins 5 and 13 in the aortic endothelial barrier,” Journal of Cellular Physiology, vol. 171, No. 3, Jun. 1997, pp. 243-251. cited by other ; Corada et al., “Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability,” Blood, vol. 97, No. 6, Mar. 15, 2001, pp. 1679-1684. cited by other ; Takeichi, Ann. Rev. Biochem. (1990), 59:237-252. cited by other ; Geiger & Ayalon, Ann. Rev. Cell Biol. (1992), 8:302-332. cited by other ; Nose et al., Cell (1988), 54:993-1001. cited by other ; Shapiro et al., Nature (1996), 374:327-337. cited by other ; Lampugnani et al., J. Cell. Biol. (1992), 118:1511-1522. cited by other ; Rabiet et al., Arterioscler. Thromb. Vasc. Biol. (1996), 16:488-496. cited by other ; Dejana, J. Clin. Invest. (1997), 100:S7-10. cited by other ; Dejana et al., Faseb J. (1995), 9:910-918. cited by other ; Dejana et al., Ann NY Acad Sci. (1997), 811:36-43. cited by other ; Kevil et al., J. Biol. Chem. (1988) 273:15099-15103. cited by other ; Yap et al., J. Cell Biol. (1998), 141:779-789. cited by other ; Faure et al., Development (1999), 128: 2093-2101. cited by other ; Ali et al., Microcirculation 4:267-277 (1997). cited by other ; Berman et al., EMBO J. 7:727-738 (1988). cited by other ; Bowie et al., Science, 247:1306-1310 (1990). cited by other ; Burgess et al., J. of Cell Bio. 111:2129-2138 (1990). cited by other ; Cole, et al., 1985, In Moloclonal Antibodies and Cancer therapy, Alan R. Liss, Inc., pp. 77-96. cited by other ; Gillman & Smith, Gene 8:81-97 (1979). cited by other ; Gotsch et al., J. Cell Sci. 110:583-588 (1997). cited by other ; Gumbiner, B., & Simons, K., Cell Biol. 102:457-468 (1996). cited by other ; Kohler & Milstein, Nature, 256:495-497 (1975). cited by other ; Kozbor et al., Immunology Today 4:72, (1983). cited by other ; Lampugnani et al., J. Cell Biol. 129:203-217 (1995). cited by other ; Lazar et al., Molecular and Cellular Biology 8:1247-1252 (1988). cited by other ; Nagar et al., Nature 380:360-364 (1996). cited by other ; Overduin et al., Science 267:386-389 (1995). cited by other ; Queen, Nature 351:501 (1991). cited by other ; Roberts, et al., Nature 328:731-734 (1987). cited by other ; Piggot et al. (1991) Structural and Functional Studies of the Endothelial Activation Antigen Endothelial Leucocyte Adhesion Molecule-1 . . . , J. Immun. 147(1): 130-135. cited by other
- Primary Examiner: Rawlings, Stephen L.
- Attorney, Agent or Firm: Lucas & Mercanti, LLP
|
